Sarepta Therapeutics (SRPT) Updates on Eteplirsen Study 202 in DMD; Decline in Walking Observed
Tweet Send to a Friend
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) announced data through Week 168 from Study 202, a Phase IIb open-label extension study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
